Uncategorized

Scholar Rock and Cure SMA Share Update on Apitegromab and FDA Meeting 

November 14, 2025
Posted in , , ,

Read the Scholar Rock community statement here.   Scholar Rock recently held an in-person Type A meeting with the FDA on November 12 to discuss […]

Read More ›

Novartis Releases Fall SMA Community Update Letter

November 3, 2025
Posted in , , ,

Novartis recently released an update on their continued collaboration with the SMA community through fundraising events and community support programs, and they will continue to […]

Read More ›

Unlock a Future of Possibilities: Cure SMA Launches Year-End Campaign

November 3, 2025
Posted in , , ,

As 2025 starts to wind down, Cure SMA is proud to launch our year-end fundraising campaign: Unlock a Future of Possibilities. This theme represents hope, […]

Read More ›

Scholar Rock Releases SMA Community Update Letter on Apitegromab

October 30, 2025
Posted in , , ,

Yesterday, Scholar Rock shared an SMA community update letter on their Biologics License Application (BLA) for apitegromab in SMA. As shared on September 23, 2025, […]

Read More ›

Biogen to Initiate Phase 3 Pivotal Study Evaluating Investigational Drug Salanersen

October 30, 2025
Posted in , , ,

Today, Biogen announced plans to initiate Phase 3 development to evaluate the effectiveness and safety of salanersen, an investigational drug for the treatment of spinal […]

Read More ›

2025 Hope on the Hill Celebrates Day of Advocacy in Washington, DC

September 17, 2025
Posted in

Cure SMA celebrated a day of advocacy on Capitol Hill on September 16 with more than 170 individuals with spinal muscular atrophy (SMA), their families, […]

Read More ›

SMA Researchers and Clinicians from Around the World Gather at the 29th Annual SMA Research & Clinical Care Meeting (2 of 2)

September 3, 2025
Posted in , , ,

At the end of June, SMA researchers and clinicians from around the world gathered in Anaheim, California, for the 29th Annual SMA Research & Clinical […]

Read More ›

Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)

January 29, 2025
Posted in , ,

  “With the strength of our Phase 3 data as the foundation of our submission, we look forward to continuing to work closely with the […]

Read More ›

Make an Impact with Cure SMA’s Mission, Milestones, Momentum Campaign

November 1, 2024
Posted in , , ,

We’re kicking off our Mission, Milestones, Momentum Year-End Campaign with an incredible $50,000 matching gift. In honor of Hunter Rhodes, living with SMA, the Johns […]

Read More ›

Registration is Open for the 2024 Annual SMA Conference!

December 7, 2023
Posted in

We are excited to announce that registration is now open for the 2024 Annual SMA Conference, which will be held at the JW Marriott Austin in […]

Read More ›
Scroll to Top